The research of Dr. Sara Vandenwijngaert, Ph.D., focuses on the role of the cyclic guanosine monophosphate (cGMP) pathway in cardiovascular disease. Sara obtained her Ph.D. in Biomedical Sciences (Cardiovascular Medicine) from the KU Leuven in Belgium. As a PhD student in the lab of Dr. Stefan Janssens , she studied the role of the cGMP-degrading enzyme phoshodiesterase type 5 (PDE5) in the pathogenesis of cardiac hypertrophy using patients samples and mouse models. In the Buys lab, she investigates the potential of the cGMP-synthetizing enzyme soluble guanylate cyclase (sGC) as a therapeutic target in chemotherapy-induced heart disease. Furthermore, Sara studies the association between single nucleotide polymorphisms (SNPs) in the sGC gene and hypertension.